Judge opts for jury trial in Alzheimer`s drug case
Allergan Recalls Viibryd Starter Kit (10 & 20 mg)
Bisaro, Amneal poach top Allergan exec for CEO`s chair
Enforcement Report - Week of June 7, 2017
It’s not the first time Saunders has shot down the possibility of picking up the embattled drugmaker. “We look to buy young products that we think we can put into our hands and do better with and really grow, or we buy R&D assets. And best I can tell, Valeant just doesn’t fit that bill,” he told CNBC last September.
New York, US-based Actinium Pharmaceuticals has appointed Gregory Bergonio as director of clinical operations, with particular responsibility for its Actimab-A phase II clinical trial programme.
Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the appointment of Michael Davidson, M.D., as chief medical officer effective December 19, 2016. His responsibilities will include the strategic development and clinical advancement of the Company’s products, which target schizophrenia (MIN-101), insomnia (MIN-202), major depressive disorder (MIN-117) and Parkinson’s disease (MIN-301).
Allergan PLC's Forest Laboratories and Forest Pharmaceuticals units will pay $38 million to settle U.S. charges that it paid physicians to prescribe three medications, the U.S. Justice Department said on Thursday.
Assisted by more than $1.4 million in tax breaks from the Suffolk County Industrial Development Agency that were granted in July, Evaric, a newly formed manufacturer of generic drugs, bought the 7.5-acre property at 155 Commerce Drive from Ropack, a Canadian pharmaceutical manufacturer.